1.
Kerelakes DJ, Obenchain RL et al. Abciximab provides cost-effective survival
advantage in high-volume interventional practice. Am. Heart J. 140:603-10;**
2000**.

2.
Obenchain RL. Resampling and multiplicity in cost-effectiveness inference.
J. Biopharmaecutical Statistics. 9(4), 563-582, 1999.

3.
Obenchain RL et al. Bootstrap analyses of cost effectiveness in antidepressant
pharmacotherapy. PharmacoEconomics. 11(5):464-472, 1997.

4.
**Briggs
AH, O’Brien BJ, and Blackhouse G.** **
Thinking outside the box: recent advances in the analysis and presentation of uncertainty
in cost-effectiveness studies**. Annual Rev. Public Health.
23:377–401, 2002.

5.
Nixon RM et al. Non-parametric methods for cost-effectiveness analysis: the central limit theorem and the bootstrap compared.
Health Economics. 19:316-333, 2010.

6.
Kim N. et al. An economic analysis of usual care and acupuncture collaborative treatment on chronic low back pain: a Markov decision analysis.
BMC Complementary and Alternative Med. 10:74, 2010.